1 10 48 https://ciencia.lugoneseditorial.com.ar/files/original/2a6c6ecb1c66dcf339c3ba8ccd8b4e46.pdf 8364899a7975703c3ef38e7d8a210c6e Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa-1/">https://lugoneseditorial.com.ar/novedades/diabetes/monitoreo-continuo-de-glucosa-1/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource ¿Por qué no todos los sistemas de monitoreo continuo de glucosa (MCG) son iguales? Description An account of the resource La FDA ha desarrollado una clasificación para los sistemas MCG que los divide en aquellos que requieren (complementarios) o no (no complementarios) del uso de tiras reactivas para la toma de decisiones seguras. Source A related resource from which the described resource is derived 1. Campbell F. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatric Diabetes 2018; 19(7):1294-1301. doi: 10.1111/pedi.12735. Publisher An entity responsible for making the resource available María Fernanda Cristoforetti Date A point or period of time associated with an event in the lifecycle of the resource 14/03/2025 Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0592">https://doi.org/10.47196/0592</a> Abbott Diabetes Clasificación MCG Diabetes MCG MCG complementario MCG no complementario monitoreo continuo de glucosa Ventajas MCG no complementarios https://ciencia.lugoneseditorial.com.ar/files/original/8948d29d3f8e50f8b0edb27e5d8e893e.pdf c6df3afbf474e320d172268355cfb9bc Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Estudio prospectivo: evaluación de la eficacia y longevidad del ácido hialurónico reticulado en relleno de surcos nasolabiales Subject The topic of the resource Dermatología Description An account of the resource Introducción: la elección de métodos mínimamente invasivos posiciona a los rellenos de ácido hialurónico (AH) como técnica líder de rejuvenecimiento facial. Los rellenos inyectables de AH se han utilizado ampliamente en el tratamiento clínico de las arrugas faciales. Sin embargo, la información adicional y la evidencia clínica sobre la longevidad del relleno de AH después de la inyección son limitadas. Objetivos: demostrar la eficacia, seguridad y longevidad de AH reticulado (AHR) 30 mg/ml (Estrianon Hyaluronic Implant 30® Allanmar International Company S.R.L., Argentina) para el relleno de surcos nasolabiales (SNL). Diseño: ensayo clínico multicéntrico, prospectivo y controlado de 12 meses de duración. Materiales y métodos: se incluyeron 160 pacientes (132 mujeres y 28 hombres, repartidos en cohortes de 30, 30 y 100 cada una) y se les aplicó un gel inyectable de AHR 30 mg/ml en la corrección de los SNL para evaluar la seguridad, eficacia y longevidad del producto. Resultados: se observó una corrección relevante de la depresión en los surcos que se mantuvo hasta el final del estudio. El nivel medio de mejora fue clínicamente significativo en el 94% de los casos. La gravedad de los SNL se redujo en aproximadamente 2 puntos hasta el rango de leve o apenas visible. Conclusiones: Estrianon Hyaluronic Implant 30® demostró ser un relleno seguro, eficaz y de longevidad considerable. A los 12 meses aún se observó corrección significativa y el tratamiento fue bien tolerado por los pacientes. Creator An entity primarily responsible for making the resource Claudio Dachevsky, Héctor Llovera Source A related resource from which the described resource is derived I. Sharma P, Sharma S. Comparative study of a new dermal filler Uma Jeunesse® and Juvéderm®. J Cosmet Dermatol 2011 Jun;10(2):118-25. doi: 10.1111/j.14732165.2011.00556.x. II. Chung C, Lee JH. A single-center, randomized, doubleblind clinical trial to compare the efficacy and safety of a new monophasic hyaluronic acid filler and biphasic filler in correcting nasolabial fold. Aesth Plast Surg 2021;45:2902-2908. doi: 10.1007/s00266-021-02252-0 III. Goldberg DJ. Breakthroughs in US dermal fillers for facial soft-tissue augmentation. J Cosmet Laser Ther 2009 Dec;11(4):240-7. doi: 10.3109/14764170903341731. IV. Gold M. The science and art of hyaluronic acid dermal filler use in esthetic applications. J Cosmet Dermatol 2009 Dec;8(4):301-7. doi: 10.1111/j.14732165.2009.00464.x. V. Beer K. Dermal fillers and combinations of fillers for facial rejuvenation. Dermatol Clin 2009 Oct;27(4):42732. doi: 10.1016/j.det.2009.08.011. VI. Grunebaum LD, Bogdan Allemann I, Dayan S, Mandy S, Baumann L. The risk of alar necrosis associated with dermal filler injection. Dermatol Surg 2009 Oct;35(Suppl 2):1635-40. doi: 10.1111/j.1524-4725.2009.01342.x. VII. Hirsch R, Stier M. Complications and their management in cosmetic dermatology. Dermatol Clin 2009 Oct;27(4):507-20. doi: 10.1016/j.det.2009.08.013. VIII. Qiao J, Jia QN, Jin HZ, Li F, He CX, Yang J, Zuo YG, Fu LQ. Long-term follow-up of longevity and diffusion pattern of hyaluronic acid in nasolabial fold correction through high-frequency ultrasound. Plast Reconstr Surg 2019 Aug;144(2):189e-196e. doi: 10.1097/ PRS.0000000000005848. IX. Young SR, Bolton PA, Downie J. Use of high-frequency ultrasound in the assessment of injectable dermal fillers. Skin Res Technol 2008 Aug;14(3):320-3. doi: 10.1111/j.1600-0846.2008.00297.x. X. Marinho A, Nunes C, Reis S. Hyaluronic acid: a key ingredient in the therapy of inflammation. Biomolecules 2021 Oct 15;11(10):1518. doi: 10.3390/biom11101518. XI. Day DJ, Littler CM, Swift RW, Gottlieb S. The Wrinkle Severity Rating Scale: a validation study. Am J Clin Dermatol 2004;5(1):49-52. doi: 10.2165/00128071200405010-00007. XII. Savoia A, Accardo C, Vannini F, Di Pasquale B, Baldi A. Outcomes in thread lift for facial rejuvenation: a study performed with happy lift™ tevitalizing. Dermatology Ther (Heidelb) 2014;4(1):103-14. doi: 10.1007/s13555014-0041-6. XIII. Sharma AN, Patel BC. Laser Fitzpatrick skin type recommendations (updated 2023 Mar 6). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023 Jan. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK557626/. XIV. Mark G. Rubin, treatment of nasolabial folds with fillers. Aesthetic Surgery Journal 2004;24(5):489-493. doi: 10.1016/j.asj.2004.06.004. XV. Shaw RB Jr, Katzel EB, Koltz PF, Yaremchuk MJ, Girotto JA, Kahn DM, Langstein HN. Aging of the facial skeleton: aesthetic implications and rejuvenation strategies. Plast Reconstr Surg 2011 Jan;127(1):374-383. doi: 10.1097/PRS.0b013e3181f95b2d. XVI. Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am 2007 Feb;15(1):63-76. doi: 10.1016/j.fsc.2006.11.002. XVII. Allergan. Instrucciones de uso. Disponible en https:// www.rxabbvie.com/pdf/juvederm-ultra_dfu.pdf. XVIII. Allergan. Instrucciones de uso. Disponible en: https:// www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf. XIX. Galderma. Instrucciones de uso. Disponible en: https:// www.galderma.com/us/sites/default/files/2018-11/ Restylane_IFU.pdf. XX. Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003 Jun;29(6):588-95. doi: 10.1046/j.15244725.2003.29150.x. XXI. Li D, Xie Y, Li Q, Sun J, Jiang P, Jia Y, Murphy DK, Li Q. Safety and effectiveness of Juvéderm Ultra Plus injectable gel in correcting severe nasolabial folds in Chinese subjects. Plast Reconstr Surg Glob Open 2017 Jan 16;5(1):e1133. doi: 10.1097/GOX.0000000000001133. XXII. Goodman GJ, Bekhor P, Rich M, Rosen RH, Halstead MB, Rogers JD. A comparison of the efficacy, safety, and longevity of two different hyaluronic acid dermal fillers in the treatment of severe nasolabial folds: a multicenter, prospective, randomized, controlled, single-blind, within-subject study. Clin Cosmet Investig Dermatol 2011;4:197-205. doi: 10.2147/CCID.S26055. XXIII. Baumann LS, Shamban AT, Lupo MP, Monheit GD, Thomas JA, Murphy DK, Walker PS; Juvéderm vs. Zyplast nasolabial fold study group. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 2007 Dec;33(Suppl 2):S128-35. doi: 10.1111/j.1524-4725.2007.33352.x. XXIV. Lupo MP, Smith SR, Thomas JA, Murphy DK, Beddingfield FC III. Effectiveness of Juvéderm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg 2008 Jan;121(1):289-297. doi: 10.1097/01. prs.0000294968.76862.83. XXV. Pinsky MA, Thomas JA, Murphy DK, Walker PS; Juvéderm vs. Zyplast Nasolabial Fold Study Group. Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J 2008 Jan-Feb;28(1):17-23. doi: 10.1016/j.asj.2007.09.005. XXVI. Solish N, Bertucci V, Percec I, Wagner T, Nogueira A, Mashburn J. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol 2019 Jun;18(3):738-746. doi: 10.1111/ jocd.12961. Publisher An entity responsible for making the resource available Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Rights Information about rights held in and over the resource Registros legales: Sello Editorial Lugones®. Director: Facundo Lugones. Editora: Lic. María Fernanda Cristoforetti. Propietaria: Editorial Biotecnológica S.R.L. Domicilio legal: Av. Curapaligüe 202, 9° B (1406), Ciudad de Buenos Aires, Argentina. Autores del artículo de Lugones Editorial: Marcelo Robles, Claudio Dachevsky, Héctor Llovera. Derechos de reproducción: Sello Editorial Lugones®, Editorial Biotecnológica S.R.L. Se prohíbe la reproducción total o parcial de los artículos sin las autorizaciones de la autora y de la editorial. Obra registrada en la Dirección Nacional del Derecho de Autor, Ministerio de Justicia y Derechos Humanos de la República Argentina. Registro de Obra Publicada-Página Web en el Legajo Nº: RL-2021-41251755-APN-DNDA#MJ. Registro de Publicaciones Periódicas en el Legajo Nº: RL-2023-71140630-APN-DNDA#MJ, Ciudad de Buenos Aires, Argentina. Format The file format, physical medium, or dimensions of the resource Página web Language A language of the resource Español e Inglés Type The nature or genre of the resource Científico Identifier An unambiguous reference to the resource within a given context <a href="https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/#">https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/#</a> Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Argentina, 2023 ácido hialurónico Global Aesthetic Improvement Scale surcos nasolabiales https://ciencia.lugoneseditorial.com.ar/files/original/30be7fd9a44d120a9881dd0404a36ae2.pdf c6df3afbf474e320d172268355cfb9bc Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Subject The topic of the resource Dermatología Title A name given to the resource Trabajos originales Publisher An entity responsible for making the resource available Sello Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Futerman International Products Format The file format, physical medium, or dimensions of the resource Página web: https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/ Language A language of the resource Español Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Prospective study: evaluation of the efficacy and longevity of cross-linked hyaluronic acid in filling nasolabial folds Subject The topic of the resource Dermatology Description An account of the resource Introduction: The choice of minimally invasive methods positions hyaluronic acid (HA) fillers as a leading facial rejuvenation technique. Injectable HA fillers have been widely used in the clinical treatment of facial wrinkles. However, additional information and clinical evidence on the longevity of HA filler after injection is limited. Objectives: demonstrate the efficacy, safety and longevity of cross-linked HA (AHR) 30 mg/ml (Estrianon Hyaluronic Implant 30® Allanmar International Company S.R.L., Argentina) for filling nasolabial folds (SNL). Design: multicenter, prospective, controlled clinical trial of 12 months duration. Materials and methods: 160 patients were included (132 women and 28 men, divided into cohorts of 30, 30 and 100 each) and an injectable gel of AHR 30 mg/ml was applied in the correction of SNL to evaluate safety. , effectiveness and longevity of the product. Results: a relevant correction of the depression in the sulci was observed that was maintained until the end of the study. The mean level of improvement was clinically significant in 94% of cases. The severity of NLS was reduced by approximately 2 points to the range of mild or barely noticeable. Conclusions: Estrianon Hyaluronic Implant 30® proved to be a safe, effective filler with considerable longevity. At 12 months, significant correction was still observed and the treatment was well tolerated by patients. Creator An entity primarily responsible for making the resource Claudio Dachevsky, Héctor Llovera Source A related resource from which the described resource is derived I. Sharma P, Sharma S. Comparative study of a new dermal filler Uma Jeunesse® and Juvéderm®. J Cosmet Dermatol 2011 Jun;10(2):118-25. doi: 10.1111/j.14732165.2011.00556.x. II. Chung C, Lee JH. A single-center, randomized, doubleblind clinical trial to compare the efficacy and safety of a new monophasic hyaluronic acid filler and biphasic filler in correcting nasolabial fold. Aesth Plast Surg 2021;45:2902-2908. doi: 10.1007/s00266-021-02252-0 III. Goldberg DJ. Breakthroughs in US dermal fillers for facial soft-tissue augmentation. J Cosmet Laser Ther 2009 Dec;11(4):240-7. doi: 10.3109/14764170903341731. IV. Gold M. The science and art of hyaluronic acid dermal filler use in esthetic applications. J Cosmet Dermatol 2009 Dec;8(4):301-7. doi: 10.1111/j.14732165.2009.00464.x. V. Beer K. Dermal fillers and combinations of fillers for facial rejuvenation. Dermatol Clin 2009 Oct;27(4):42732. doi: 10.1016/j.det.2009.08.011. VI. Grunebaum LD, Bogdan Allemann I, Dayan S, Mandy S, Baumann L. The risk of alar necrosis associated with dermal filler injection. Dermatol Surg 2009 Oct;35(Suppl 2):1635-40. doi: 10.1111/j.1524-4725.2009.01342.x. VII. Hirsch R, Stier M. Complications and their management in cosmetic dermatology. Dermatol Clin 2009 Oct;27(4):507-20. doi: 10.1016/j.det.2009.08.013. VIII. Qiao J, Jia QN, Jin HZ, Li F, He CX, Yang J, Zuo YG, Fu LQ. Long-term follow-up of longevity and diffusion pattern of hyaluronic acid in nasolabial fold correction through high-frequency ultrasound. Plast Reconstr Surg 2019 Aug;144(2):189e-196e. doi: 10.1097/ PRS.0000000000005848. IX. Young SR, Bolton PA, Downie J. Use of high-frequency ultrasound in the assessment of injectable dermal fillers. Skin Res Technol 2008 Aug;14(3):320-3. doi: 10.1111/j.1600-0846.2008.00297.x. X. Marinho A, Nunes C, Reis S. Hyaluronic acid: a key ingredient in the therapy of inflammation. Biomolecules 2021 Oct 15;11(10):1518. doi: 10.3390/biom11101518. XI. Day DJ, Littler CM, Swift RW, Gottlieb S. The Wrinkle Severity Rating Scale: a validation study. Am J Clin Dermatol 2004;5(1):49-52. doi: 10.2165/00128071200405010-00007. XII. Savoia A, Accardo C, Vannini F, Di Pasquale B, Baldi A. Outcomes in thread lift for facial rejuvenation: a study performed with happy lift™ tevitalizing. Dermatology Ther (Heidelb) 2014;4(1):103-14. doi: 10.1007/s13555014-0041-6. XIII. Sharma AN, Patel BC. Laser Fitzpatrick skin type recommendations (updated 2023 Mar 6). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2023 Jan. Disponible en: https://www.ncbi.nlm.nih.gov/ books/NBK557626/. XIV. Mark G. Rubin, treatment of nasolabial folds with fillers. Aesthetic Surgery Journal 2004;24(5):489-493. doi: 10.1016/j.asj.2004.06.004. XV. Shaw RB Jr, Katzel EB, Koltz PF, Yaremchuk MJ, Girotto JA, Kahn DM, Langstein HN. Aging of the facial skeleton: aesthetic implications and rejuvenation strategies. Plast Reconstr Surg 2011 Jan;127(1):374-383. doi: 10.1097/PRS.0b013e3181f95b2d. XVI. Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am 2007 Feb;15(1):63-76. doi: 10.1016/j.fsc.2006.11.002. XVII. Allergan. Instrucciones de uso. Disponible en https:// www.rxabbvie.com/pdf/juvederm-ultra_dfu.pdf. XVIII. Allergan. Instrucciones de uso. Disponible en: https:// www.rxabbvie.com/pdf/juvederm-ultra-plus-xc_dfu.pdf. XIX. Galderma. Instrucciones de uso. Disponible en: https:// www.galderma.com/us/sites/default/files/2018-11/ Restylane_IFU.pdf. XX. Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003 Jun;29(6):588-95. doi: 10.1046/j.15244725.2003.29150.x. XXI. Li D, Xie Y, Li Q, Sun J, Jiang P, Jia Y, Murphy DK, Li Q. Safety and effectiveness of Juvéderm Ultra Plus injectable gel in correcting severe nasolabial folds in Chinese subjects. Plast Reconstr Surg Glob Open 2017 Jan 16;5(1):e1133. doi: 10.1097/GOX.0000000000001133. XXII. Goodman GJ, Bekhor P, Rich M, Rosen RH, Halstead MB, Rogers JD. A comparison of the efficacy, safety, and longevity of two different hyaluronic acid dermal fillers in the treatment of severe nasolabial folds: a multicenter, prospective, randomized, controlled, single-blind, within-subject study. Clin Cosmet Investig Dermatol 2011;4:197-205. doi: 10.2147/CCID.S26055. XXIII. Baumann LS, Shamban AT, Lupo MP, Monheit GD, Thomas JA, Murphy DK, Walker PS; Juvéderm vs. Zyplast nasolabial fold study group. Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 2007 Dec;33(Suppl 2):S128-35. doi: 10.1111/j.1524-4725.2007.33352.x. XXIV. Lupo MP, Smith SR, Thomas JA, Murphy DK, Beddingfield FC III. Effectiveness of Juvéderm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg 2008 Jan;121(1):289-297. doi: 10.1097/01. prs.0000294968.76862.83. XXV. Pinsky MA, Thomas JA, Murphy DK, Walker PS; Juvéderm vs. Zyplast Nasolabial Fold Study Group. Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness. Aesthet Surg J 2008 Jan-Feb;28(1):17-23. doi: 10.1016/j.asj.2007.09.005. XXVI. Solish N, Bertucci V, Percec I, Wagner T, Nogueira A, Mashburn J. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol 2019 Jun;18(3):738-746. doi: 10.1111/ jocd.12961. Publisher An entity responsible for making the resource available Editorial Lugones Date A point or period of time associated with an event in the lifecycle of the resource 12/12/2023 Contributor An entity responsible for making contributions to the resource Allanmar International Company S.R.L Rights Information about rights held in and over the resource Legal records: Lugones® Editorial Seal. Director: Facundo Lugones. Editor: Lic. María Fernanda Cristoforetti. Owner: Editorial Biotecnológica S.R.L. Legal address: Av. Curapaligüe 202, 9° B (1406), City of Buenos Aires, Argentina. Authors of the Lugones article Editorial: Marcelo Robles, Claudio Dachevsky, Héctor Llovera Reproduction rights: Lugones® Editorial Seal, Editorial Biotecnológica S.R.L. Total or partial reproduction of the articles is prohibited without the authorization of the author and the publisher. Work registered in the National Directorate of Copyright, Ministry of Justice and Human Rights of the Argentine Republic. Registration of Published Work-Web Page in File No.: RL-2021-41251755-APN-DNDA#MJ. Registration of Periodical Publications in File No.: RL-2023-71140630-APN-DNDA#MJ, City of Buenos Aires, Argentina. Format The file format, physical medium, or dimensions of the resource Website Language A language of the resource English and spanish Type The nature or genre of the resource Scientific Identifier An unambiguous reference to the resource within a given context <a href="https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/#">https://www.lugoneseditorial.com.ar/novedades/estudio-prospectivo-evaluacion-de-la-eficacia-y-longevidad-del-acido-hialuronico-reticulado-en-relleno-de-surcos-nasolabiales/#</a> Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Argentina, 2023 Global Aesthetic Improvement hyaluronic acid nasolabial folds Website A resource comprising of a web page or web pages and all related assets ( such as images, sound and video files, etc. ). Local URL The URL of the local directory containing all assets of the website <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/tratamiento-pie-diabetico/">https://lugoneseditorial.com.ar/novedades/dermatologia/tratamiento-pie-diabetico/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Abordaje y tratamiento del pie diabético Description An account of the resource El abordaje del pie diabético implica un proceso multidisciplinario y para su tratamiento la enzima proteolítica colagenasa demostró ser una aliada invaluable para la cicatrización de heridas, con excelente tolerancia. Creator An entity primarily responsible for making the resource Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Source A related resource from which the described resource is derived 1. International Diabetes Federation. IDF Diabetes Atlas, 10th ed. https://diabetesatlas.org/atlas/tenth-edition/ 2. Instituto Nacional de Estadística y Censos (INDEC). Cuarta Encuesta Nacional de Factores de Riesgo. Resultados definitivos. 1a ed. Ciudad Autónoma de Buenos Aires. 3. Zhang Y, Lazzarini PA, McPhail SM, vanNetten JJ, Armstrong DG, Pacella RE. Global disability burdens of diabetes-related lower-extremity complications in 1990 and 2016. Diabetes Care 2020;43(5):964974. doi:10.2337/dc19-1614. 4. Boulton AJ. The pathway to foot ulceration in diabetes. Med Clin North Am 2013;97:775-790 (2013). doi: 10.1016/j.mcna.2013.03.007. 5. Armstrong DG, Boulton AJM, BusSA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017; 376(24):2367-2375. doi:10.1056/NEJMra1615439. 6. Ndosi M, Wright-Hughes A, Brown S, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med 2018;35(1):78-88. doi:10.1111/dme.13537. 7. Carro GV, Saurral R, Sagüez FS, Witman EL, Carrió M, Duturo CF, Dicatarina-Losada, MV, Braver JD, Illuminati G, Torres JC, David RA, Maldonado N. (2023). Estudio de diabetes mellitus y pie diabético en la internación: datos de Argentina. Rev Soc Arg Diab 2019;53(1):3-15. doi: 10.47196/diab.v53i1.136. 8. Senneville É, Albalawi Z, van Asten SA, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes: IWGDF/IDSA 2023. Diabetes Metab Rews Rev 2024;40(3):e3687. doi: 10.1002/dmrr.3687. 9. Ministerio de Salud de la Nación Argentina. Pautas para la prevención y el abordaje del pie diabético. Disponible en: https://bancos.salud.gob.ar/recurso/pautas-para-la-prevencion-y-el-abordaje-del-pie-diabetico. 10. IWGDF 2023 update. Guidelines on the classification of foot ulcers in people with diabetes. Disponible en: IWGDF Classification Guideline 2023 https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-2023-03-Classification-Guideline.pdf 11. Carro GV, Saurral R, Carlucci E, Gette F, Llanos MLÁ, Amato PS. A comparison between diabetic foot classifications WIfI, Saint Elian, and Texas. Description of wounds and clinical outcomes. Int J Low Extrem Wounds 2022 Jun;21(2):120-130. doi: 10.1177/1534734620930171. 12. Carro GV, Saurral RN, Issa CM, Witman EL, Carrió M. Validación de clasificaciones de pie diabético en Argentina. Rev Soc Arg Diab 2023;57(2):84-94. doi: 10.47196/diab.v57i2.625. 13. Lazzarini PA, Pacella RE, Armstrong DG, van Netten JJ. Diabetes-related lower-extremity complications are a leading cause of the global burden of disability. Diabet Med 2018 May 23. doi: 10.1111/dme.13680. 14. Vainieri E, Ahluwalia R, Slim H, Vas PRJ. Outcomes after emergency admission with a diabetic foot attack indicate a high rate of healing and limb salvage but increased mortality: 18-month follow-up study. Exp Clin Endocrinol Diabetes 2022 Mar;130(3):165-171. doi: 10.1055/a-1322-4811. 15. Atkin L, Bućko Z, Conde-Montero E. Implementing TIMERS: the race against hard-to-heal wounds. J Wound Care 2019 Mar 1;23(Sup3a):S1-S50. doi: 10.12968/jowc.2019.28.Sup3a.S1. 16. Lantis-li JCL, Gordon I. Clostridial collagenase for the management of diabetic foot ulcers. Results of four randomized controlled trials. Wounds 2017;29(10):297-305. doi: 10.25270/wnds/2017.10.297305. 17. De Decker I, De Graeve L, Hoeksema H, Monstrey S, Verbelen J, De Coninck P, Vanlerberghe E, Claes KEY. Enzymatic debridement: past, present, and future. Acta Chir Belg 2022 Aug;122(4):279-295. doi: 10.1080/00015458.2022.2068746. 18. Chen L, Sun S, Gao Y, Ran X. Global mortality of diabetic foot ulcer. A systematic review and meta-analysis of observational studies. Diabetes Obes Metab 2023;25(1):36-45. doi: 10.1111/dom.14840. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 05/11/2024 Contributor An entity responsible for making contributions to the resource Abbott Laboratories Language A language of the resource Español Abbott Abordaje Diabetes Enzima proteolítica colagenasa Mabel Carrió pie diabético Tratamiento Úlcera pie diabético Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/tratamiento-pie-diabetico/">https://lugoneseditorial.com.ar/novedades/dermatologia/tratamiento-pie-diabetico/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Approach and treatment of diabetic foot Subject The topic of the resource The approach to diabetic foot involves a multidisciplinary process and for its treatment the proteolytic enzyme collagenase proved to be an invaluable ally for wound healing, with excellent tolerance. Description An account of the resource Interview with Dr. Mabel Carrió (M.N. 68739), Diabetologist, Director of the Dr. Alberto Maggio Municipal Diabetes Center and the Malvinas Argentinas Diabetic Foot Day Hospital, Director of the Diabetic Foot Diploma, Universidad Nacional del Nordeste (UNNE) Creator An entity primarily responsible for making the resource Mabel Carrió Source A related resource from which the described resource is derived 1. International Diabetes Federation. IDF Diabetes Atlas, 10th ed. https://diabetesatlas.org/atlas/tenth-edition/ 2. Instituto Nacional de Estadística y Censos (INDEC). Cuarta Encuesta Nacional de Factores de Riesgo. Resultados definitivos. 1a ed. Ciudad Autónoma de Buenos Aires. 3. Zhang Y, Lazzarini PA, McPhail SM, vanNetten JJ, Armstrong DG, Pacella RE. Global disability burdens of diabetes-related lower-extremity complications in 1990 and 2016. Diabetes Care 2020;43(5):964974. doi:10.2337/dc19-1614. 4. Boulton AJ. The pathway to foot ulceration in diabetes. Med Clin North Am 2013;97:775-790 (2013). doi: 10.1016/j.mcna.2013.03.007. 5. Armstrong DG, Boulton AJM, BusSA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017; 376(24):2367-2375. doi:10.1056/NEJMra1615439. 6. Ndosi M, Wright-Hughes A, Brown S, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med 2018;35(1):78-88. doi:10.1111/dme.13537. 7. Carro GV, Saurral R, Sagüez FS, Witman EL, Carrió M, Duturo CF, Dicatarina-Losada, MV, Braver JD, Illuminati G, Torres JC, David RA, Maldonado N. (2023). Estudio de diabetes mellitus y pie diabético en la internación: datos de Argentina. Rev Soc Arg Diab 2019;53(1):3-15. doi: 10.47196/diab.v53i1.136. 8. Senneville É, Albalawi Z, van Asten SA, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes: IWGDF/IDSA 2023. Diabetes Metab Rews Rev 2024;40(3):e3687. doi: 10.1002/dmrr.3687. 9. Ministerio de Salud de la Nación Argentina. Pautas para la prevención y el abordaje del pie diabético. Disponible en: https://bancos.salud.gob.ar/recurso/pautas-para-la-prevencion-y-el-abordaje-del-pie-diabetico. 10. IWGDF 2023 update. Guidelines on the classification of foot ulcers in people with diabetes. Disponible en: IWGDF Classification Guideline 2023 https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-2023-03-Classification-Guideline.pdf 11. Carro GV, Saurral R, Carlucci E, Gette F, Llanos MLÁ, Amato PS. A comparison between diabetic foot classifications WIfI, Saint Elian, and Texas. Description of wounds and clinical outcomes. Int J Low Extrem Wounds 2022 Jun;21(2):120-130. doi: 10.1177/1534734620930171. 12. Carro GV, Saurral RN, Issa CM, Witman EL, Carrió M. Validación de clasificaciones de pie diabético en Argentina. Rev Soc Arg Diab 2023;57(2):84-94. doi: 10.47196/diab.v57i2.625. 13. Lazzarini PA, Pacella RE, Armstrong DG, van Netten JJ. Diabetes-related lower-extremity complications are a leading cause of the global burden of disability. Diabet Med 2018 May 23. doi: 10.1111/dme.13680. 14. Vainieri E, Ahluwalia R, Slim H, Vas PRJ. Outcomes after emergency admission with a diabetic foot attack indicate a high rate of healing and limb salvage but increased mortality: 18-month follow-up study. Exp Clin Endocrinol Diabetes 2022 Mar;130(3):165-171. doi: 10.1055/a-1322-4811. 15. Atkin L, Bućko Z, Conde-Montero E. Implementing TIMERS: the race against hard-to-heal wounds. J Wound Care 2019 Mar 1;23(Sup3a):S1-S50. doi: 10.12968/jowc.2019.28.Sup3a.S1. 16. Lantis-li JCL, Gordon I. Clostridial collagenase for the management of diabetic foot ulcers. Results of four randomized controlled trials. Wounds 2017;29(10):297-305. doi: 10.25270/wnds/2017.10.297305. 17. De Decker I, De Graeve L, Hoeksema H, Monstrey S, Verbelen J, De Coninck P, Vanlerberghe E, Claes KEY. Enzymatic debridement: past, present, and future. Acta Chir Belg 2022 Aug;122(4):279-295. doi: 10.1080/00015458.2022.2068746. 18. Chen L, Sun S, Gao Y, Ran X. Global mortality of diabetic foot ulcer. A systematic review and meta-analysis of observational studies. Diabetes Obes Metab 2023;25(1):36-45. doi: 10.1111/dom.14840. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti Date A point or period of time associated with an event in the lifecycle of the resource 5/11/2024 Abbott Approach Collagenase proteolytic enzyme Diabetes diabetic foot Diabetic foot ulcer Mabel Carrió Treatment https://ciencia.lugoneseditorial.com.ar/files/original/346919a2e18fccdbbc3063f374bb9f8e.pdf 0f9f098fd0af1af0e155d27562918a2b Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/diabetes/attd-2025/">https://lugoneseditorial.com.ar/novedades/diabetes/attd-2025/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource ATTD 2025: ciencia y tecnología Description An account of the resource En el ATTD 2025 los ejes fueron la identificación del riesgo de desarrollar diabetes tipo 1, los avances de la insulina inhalada y la investigación de insulinas sensibles a la glucosa, entre otros temas. Creator An entity primarily responsible for making the resource La Dra. Natalia Nardelli, Médica especialista en Medicina Interna, Nutrición y Diabetes (Sociedad Argentina de Diabetes, SAD). Publisher An entity responsible for making the resource available María Fernanda Cristoforetti Contributor An entity responsible for making contributions to the resource Sanofi Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0593">https://doi.org/10.47196/0593</a> ATTD 2025 Diabetes Diabetes tipo 1 Diabetes tipo 2 Etiquetas18ºInternational Conference on Advanced Technologies and Treatments for Diabetes Insulina inhalada Inteligencia artificial monitoreo continuo de glucosa Natalia Nardelli Sanofi Tecnología diabetes https://ciencia.lugoneseditorial.com.ar/files/original/b1a979afe3f1ddc6ab76687d08dfae74.pdf 0f9f098fd0af1af0e155d27562918a2b Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/diabetes/attd-2025/">https://lugoneseditorial.com.ar/novedades/diabetes/attd-2025/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource ATTD 2025: Science and Technology Description An account of the resource At ATTD 2025, the main topics were identifying the risk of developing type 1 diabetes, advances in inhaled insulin, and research into glucose-sensitive insulins, among other topics. Creator An entity primarily responsible for making the resource Natalia Nardelli, Medical Specialist in Internal Medicine, Nutrition and Diabetes (Argentine Diabetes Society, SAD). Publisher An entity responsible for making the resource available María Fernanda Cristoforetti Date A point or period of time associated with an event in the lifecycle of the resource 10/04/2025 Contributor An entity responsible for making contributions to the resource Sanofi Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0593">https://doi.org/10.47196/0593</a> 18th International Conference on Advanced Technologies and Treatments for Diabetes Artificial intelligence ATTD 2025 continuous glucose monitoring Diabetes Diabetes Technology Inhaled Insulin Natalia Nardelli Sanofi Type 1 Diabetes Type 2 Diabetes Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/dermatologia/autoanticuerpos-enfermedades-ampollares/">https://lugoneseditorial.com.ar/dermatologia/autoanticuerpos-enfermedades-ampollares/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Autoanticuerpos en enfermedades ampollares Creator An entity primarily responsible for making the resource Entrevista con el Dr. Julián Reigosa, Bioquímico, Director Técnico, Laboratorio Roquel S.R.L. Publisher An entity responsible for making the resource available Lic. María Fernanda Cristoforetti, Editora de Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 14/04/2026 Contributor An entity responsible for making contributions to the resource Laboratorios Roquel Análisis clínicos Autoanticuerpos Detección autoanticuerpos Detección enfermedades ampollares Enfermedades ampollares Histopatología Inmunofluorescencia directa Laboratorio Roquel Panel de autoanticuerpos Serología https://ciencia.lugoneseditorial.com.ar/files/original/12ca7f9469f79a235571b95fde62f9eb.pdf 08e3f3121b209b4913ca9183e352312a Hyperlink A link, or reference, to another resource on the Internet. URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/inyecciones-botox-bienestar/">https://lugoneseditorial.com.ar/novedades/dermatologia/inyecciones-botox-bienestar/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Botox injections and wellness Description An account of the resource Review analyzing the impact of Botox injections on psychological well-being and quality of life. Source A related resource from which the described resource is derived - Novo Pereiraa I, Hassan H. Impact of botulinum toxin for facial aesthetics on psychological well-being and quality of life: Evidence-based review. PRRAS 2020;75(12). Date A point or period of time associated with an event in the lifecycle of the resource 10/04/2025 Contributor An entity responsible for making contributions to the resource Import Velez Identifier An unambiguous reference to the resource within a given context <a href="https://doi.org/10.47196/0594">https://doi.org/10.47196/0594</a> Bótox Botox injections Botulinum toxin Facial rejuvenation Import Velez Psychological well-being quality of life Satisfaction https://ciencia.lugoneseditorial.com.ar/files/original/fae7fc727b7cec893cd1a699fd08f204.pdf 5e9f126e925d57252fa6089324399bad Hyperlink A link, or reference, to another resource on the Internet. Local URL The URL of the local directory containing all assets of the website <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/</a> URL <a href="https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/">https://lugoneseditorial.com.ar/novedades/dermatologia/hidroxiapatita-de-calcio-surcos-nasolabiales/</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Calcium hydroxyapatite in nasolabial folds Description An account of the resource Evaluation of the safety and efficacy of calcium hydroxyapatite in the treatment of nasolabial folds. Creator An entity primarily responsible for making the resource Editor: María Fernanda Cristoforetti Source A related resource from which the described resource is derived I. Vera-Ramírez V, Morales-Sánchez MA, Santa-Cruz FJ, Medina-Bojórquez A. Escalas clínicas para evaluar el envejecimiento cutáneo: una revisión de la literatura. Rev Centro Dermatol Pascua 2021;2:68-75. doi: 10.35366/101176. II. Li K, Meng F, Li YR, Tian Y, Chen H, Jia Q, Cai H, Jiang HB. Application of nonsurgical modalities in improving facial aging. Int J Dent 2022 Feb 24;2022:8332631. doi: 10.1155/2022/8332631. III. Ogden S, Griffiths TW. A review of minimally invasive cosmetic procedures. Br J Dermatol 2008;159:1036-1050. doi: 10.1111/j.1365-2133.2008 .08845.x. IV. Sánchez-Carpintero I, Candelas D, Ruiz-Rodríguez R. Dermal fillers: types, indications, and complications. Actas Dermosifilogr 2010;101(5):381-393. doi: 10.1016/j.ad.2010.01.004 V. Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J 2010 Mar;30(2):235-8. doi: 10.1177/1090820X10366549. Publisher An entity responsible for making the resource available Lugones Editorial Date A point or period of time associated with an event in the lifecycle of the resource 08/07/2024 Format The file format, physical medium, or dimensions of the resource Website Language A language of the resource Español calcium hydroxyapatite dermal fillers duration efficacy nasolabial folds safety